Wen-Kai Hsiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen-Kai Hsiao has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Amrit Paudel
Research Center Pharmaceutical Engineering GmbH, Graz, Austria
3 shared publications - Johannes Gregor Khinast
Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13/III, 8010 Graz, Austria
3 shared publications Barbara Lorber
Faculty of Technical Chemistry, Chemical and Process Engineering and Biotechnology, Graz University of Technology , Graz, Austria
2 shared publicationsTheresa R. Hörmann
Research Center Pharmaceutical Engineering GmbH, Graz, Austria; European Consortium of Continuous Pharmaceutical Manufacturing (eccpm.com); Graz University of Technology, Graz, Austria
2 shared publications- Anna-Laurence Schachner-Nedherer
Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Medical Physics and Biophysics, Medical University of Graz, 8010 Graz, Austria
1 shared publication - Anssi-Pekka Karttunen
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- 21 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114401
Predicting human subcutaneous bioavailability of monoclonal antibodies using an open flow microperfusion porcine model
- 21 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114401
Predicting human subcutaneous bioavailability of monoclonal antibodies using an open flow microperfusion porcine model
- Open Access
- 17 September 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 203, 106913
Opportunities of topical drug products in a changing dermatological landscape
- 17 September 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 203, 106913
Open AccessOpportunities of topical drug products in a changing dermatological landscape
- Open Access
- 24 May 2022
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 18 (2) , 497-505
Can Liposomes Survive Inkjet Printing? The Effect of Jetting on Key Liposome Attributes for Drug Delivery Applications
Purpose: Inkjet printing has the potential to enable novel personalized and tailored drug therapies based on liposome and lipid nanoparticles. However, due to the significant shear force exerted on the jetted fluids, its suitability for shear-sensitive materials such as liposomes, has not been verified. We have conducted a proof-of-concept study to examine whether the particle concentration and size distribution of placebo liposomes are affected by common inkjet/dispensing technologies. Methods: We have subjected three types of liposome-containing fluids (“inks”) to two different commercial dispensing/jetting technologies, which are relevant to most drug printing approaches. The liposome jetting processes were observed in real-time using strobographic imaging techniques. The phospholipid concentrations and particle size distributions were determined before and after jetting via enzymatic colorimetric and dynamic light scattering methods, respectively. Results: Our results have shown that the jetting dynamics of the liposome inks are well predicted by the established inkjet printing regime map based on their physical properties and the jetting conditions. Importantly, although significant shear forces were confirmed during jetting, the liposome concentrations and particle size distributions in the collected samples remain largely unaffected. Conclusion: These findings, we believe, provide the essential proof-of-concept to encourage further development in this highly topical research area.
- 24 May 2022
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 18 (2) , 497-505
Open AccessCan Liposomes Survive Inkjet Printing? The Effect of Jetting on Key Liposome Attributes for Drug Delivery Applications
Purpose: Inkjet printing has the potential to enable novel personalized and tailored drug therapies based on liposome and lipid nanoparticles. However, due to the significant shear force exerted on the jetted fluids, its suitability for shear-sensitive materials such as liposomes, has not been verified. We have conducted a proof-of-concept study to examine whether the particle concentration and size distribution of placebo liposomes are affected by common inkjet/dispensing technologies. Methods: We have subjected three types of liposome-containing fluids (“inks”) to two different commercial dispensing/jetting technologies, which are relevant to most drug printing approaches. The liposome jetting processes were observed in real-time using strobographic imaging techniques. The phospholipid concentrations and particle size distributions were determined before and after jetting via enzymatic colorimetric and dynamic light scattering methods, respectively. Results: Our results have shown that the jetting dynamics of the liposome inks are well predicted by the established inkjet printing regime map based on their physical properties and the jetting conditions. Importantly, although significant shear forces were confirmed during jetting, the liposome concentrations and particle size distributions in the collected samples remain largely unaffected. Conclusion: These findings, we believe, provide the essential proof-of-concept to encourage further development in this highly topical research area.
- 1 December 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 591, 120015
Investigation into powder tribo–charging of pharmaceuticals. Part II: Sensitivity to relative humidity
- 1 December 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 591, 120015
Investigation into powder tribo–charging of pharmaceuticals. Part II: Sensitivity to relative humidity
- 3 June 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (7) , 899-902
Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?. Expert Opinion on Drug Delivery. Accepted 18 May 2020.
- 3 June 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (7) , 899-902
Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?. Expert Opinion on Drug Delivery. Accepted 18 May 2020.
- 1 April 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (4) , 800-806
Feeding of particle-based materials in continuous solid dosage manufacturing: a material science perspective
- 1 April 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (4) , 800-806
Feeding of particle-based materials in continuous solid dosage manufacturing: a material science perspective
- 1 May 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 563, 184-197
Measurement of residence time distributions and material tracking on three continuous manufacturing lines
- 1 May 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 563, 184-197
Measurement of residence time distributions and material tracking on three continuous manufacturing lines
- 20 March 2017
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 15 (1) , 1-4
3D printing of oral drugs: a new reality or hype?
In 2015, the U.S. Food and Drug Administration approved Spritam® by Aprecia Pharmaceuticals, the first drug manufactured using 3D printing technology (3DP). While many have heralded this as a revol...
- 20 March 2017
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 15 (1) , 1-4
3D printing of oral drugs: a new reality or hype?
In 2015, the U.S. Food and Drug Administration approved Spritam® by Aprecia Pharmaceuticals, the first drug manufactured using 3D printing technology (3DP). While many have heralded this as a revol...